2-[[(E)-hex-2-enoyl]amino]acetic acid | 1197374-25-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[[(E)-hex-2-enoyl]amino]acetic acid
• CAS: 1197374-25-6
• 化学式: C₈H₁₃NO₃
• 分子量: 171.196
• InChiKey: AAPHATPOQGNLOZ-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  丙二酸环(亚)异丙酯 、 2-[[(E)-hex-2-enoyl]amino]acetic acid 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以60%的产率得到(E)-N-(2-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)-2-hydroxyethyl)hex-2-enamide
  参考文献：
  名称：

  Tetramic Acids as Scaffolds: Synthesis, Tautomeric and Antibacterial Behaviour

  摘要：

  报道了四咪酸在环氮上有各种取代基的高效合成途径、它们在溶液中的互变行为及其抗菌活性。

  DOI：

  10.1055/s-0029-1217745
• 作为产物：
  描述：

  N-hex-2-enoyl-glycine ethyl ester 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以90%的产率得到2-[[(E)-hex-2-enoyl]amino]acetic acid
  参考文献：
  名称：

  Tetramic Acids as Scaffolds: Synthesis, Tautomeric and Antibacterial Behaviour

  摘要：

  报道了四咪酸在环氮上有各种取代基的高效合成途径、它们在溶液中的互变行为及其抗菌活性。

  DOI：

  10.1055/s-0029-1217745

文献信息

• Motualevic acids and analogs: Synthesis and antimicrobial structure–activity relationships
  作者：Pradeep Cheruku、Jessica L. Keffer、Cajetan Dogo-Isonagie、Carole A. Bewley

  DOI：10.1016/j.bmcl.2010.05.073

  日期：2010.7

  Synthesis of the marine natural products motualevic acids A, E, and analogs in which modifications have been made to the ω-brominated lipid (E)-14,14-dibromotetra-deca-2,13-dienoic acid or amino acid unit are reported, together with antimicrobial activities against Staphylococcus aureus, methicillin-resistant S. aureus, Enterococcus faecium, and vancomycin-resistant Enterococcus.

  海洋天然产物 motualevic 酸 A、E 和类似物的合成，其中已对 ω-溴化脂质 ( E )-14,14-dibromotetra-deca-2,13-dienoic 酸或氨基酸单元进行了修饰，用针对抗微生物活性一起金黄色葡萄球菌，耐甲氧西林金黄色葡萄球菌，屎肠球菌，和耐万古霉素肠球菌。
• THERAPEUTIC SYSTEMS USING MAGNETIC FIELDS
  申请人：University of Iowa Research Foundation

  公开号：US20210052910A1

  公开（公告）日：2021-02-25

  A system may comprise one, two or more magnetic field systems. The magnetic field system may be configured to provide a magnetic field in a first direction to the tissue. The magnetic field system may include at least one magnetic field source to produce the magnetic field. The magnetic field produced by the at least one magnetic field source may include a magnetic field produced by at least one of a permanent magnet, a temporary magnet or electric current flow through a conductor. The same or a second magnetic field system may be configured to provide a second magnetic field in a second direction to the tissue. The magnetic field system may include two or more sources to provide the magnetic field in a second, third or fourth direction that is non-parallel to the first direction.
• MONITORING EFFICACY OF MAGNETIC AND ELECTRIC FIELDS USING BIOMARKERS
  申请人：University of Iowa Research Foundation

  公开号：US20220118269A1

  公开（公告）日：2022-04-21

  An example may deliver a therapy by delivering energy to tissue. A method may include delivering energy to the tissue by providing a magnetic field in a first direction to the tissue using a magnetic field system including a magnetic field source to produce the magnetic field, wherein the magnetic field produced by the magnetic field source includes a magnetic field produced by at least one of a permanent magnet, a temporary magnet or electric current flow through a conductor, and providing an electric field in a second direction to the tissue using an electric field system including an electric field source to produce the electric field, wherein the second direction is non-parallel to the first direction. The method may further include detecting biomarker(s) within at least one of a redox system and a metabolic system to monitor efficacy of the therapy and/or calibrate or adjust the therapy.